Recent developments include patent applications and acquisitions, corporate transactions, and clinical trial progress.

• SciSparc shares declined following a patent application for depression therapy by partner Clearmind Medicine in Hong Kong [N1].
• The company’s subsidiary NeuroThera moved to acquire a majority stake in CliniQuantum, coinciding with a 14% share price decline [N2].
• SciSparc signed a definitive agreement to acquire a patent portfolio for endoscopic technologies, entering a multi-billion dollar market opportunity [N4].
• The company’s stock surged 50% pre-market after N2OFF approved the acquisition of MitoCareX [N5].
• Shareholders approved a proposed merger with Israel-based AutoMax Motors [N6].
• SciSparc regained compliance with Nasdaq listing rules following corporate actions [N7].
• The company announced publication of a novel Japanese patent for enhanced pain management therapy combining Paracetamol and PEA [N8].

SciSparc's clinical-stage cannabinoid drug candidates address significant unmet medical needs in neurological and neuropsychiatric disorders. Positive Phase IIa trial results and regulatory approvals for Phase IIb trials in multiple countries demonstrate progress in clinical development. The company's expanding patent portfolio, including recent acquisitions in endoscopic technologies and collaborations for depression therapy, may broaden its market opportunities. The nutraceutical business provides some revenue diversification. Successful advancement through clinical trials and regulatory pathways could enhance the company's position in the cannabinoid pharmaceutical market.

SciSparc operates in a highly competitive and regulated pharmaceutical environment with significant clinical and regulatory risks. The company has a history of operating losses and an accumulated deficit, with limited revenue primarily from nutraceutical sales. Its cash position and liquidity ratios indicate potential funding constraints, and the company depends on raising additional capital to continue operations and clinical development. Clinical trial outcomes are uncertain, and regulatory approvals are not guaranteed. Market acceptance, pricing pressures, and reimbursement challenges in the cannabinoid pharmaceutical space may limit commercial success. Corporate restructuring and share consolidations may reflect financial and operational challenges.

SciSparc's moat is based on its proprietary cannabinoid pharmaceutical formulations combining THC or CBD with its proprietary CannAmide™ (PEA) technology, which aims to induce a 'sparing effect' for treating central nervous system disorders. The company has developed a portfolio of clinical-stage drug candidates with regulatory approvals to conduct trials in multiple jurisdictions, including the US, Germany, and Israel. Its intellectual property includes patents and patent applications in key therapeutic areas such as Tourette Syndrome, Alzheimer's disease, and addiction treatments. However, the pharmaceutical cannabinoid space is competitive with several established and emerging players, and the company faces challenges related to clinical development, regulatory approval, and financing.

• Clinical and Regulatory Risk: The success of SciSparc's drug candidates depends on positive clinical trial outcomes and regulatory approvals, which are uncertain and may require additional studies or data.
• Financial and Liquidity Risk: The company has incurred significant losses and has limited cash resources, with liquidity ratios below 1, indicating potential challenges in funding ongoing operations and clinical development without additional financing.
• Competitive Risk: SciSparc faces competition from established pharmaceutical companies and other cannabinoid-based drug developers with potentially greater resources and market presence.
• Market and Reimbursement Risk: Pricing pressures, reimbursement limitations, and cost-containment measures in healthcare systems may affect the commercial viability of SciSparc's products.
• Operational Risk: Dependence on key subsidiaries, partnerships, and the nutraceutical business exposes the company to operational risks including supply chain, regulatory compliance, and market acceptance.

• SciSparc Ltd. is an Israeli company incorporated in 2004, headquartered in Tel Aviv, and listed on Nasdaq under ticker SPRC [S1].
• The company operates primarily through its majority-owned subsidiary NeuroThera, focusing on clinical-stage pharmaceutical development based on cannabinoid pharmaceuticals [S1].
• Key drug candidates include SCI-110 (based on THC and CannAmide™) targeting Tourette Syndrome (TS), Alzheimer's disease and agitation, and SCI-210 (based on CBD and CannAmide™) targeting Autism Spectrum Disorder (ASD) and Status Epilepticus (SE) [S1].
• SCI-110 has completed Phase IIa clinical trials for TS and Alzheimer's disease with positive safety and tolerability results, and Phase IIb trials have been approved and initiated in Germany, Israel, and the US [S1].
• SCI-210 is in a randomized, double-blind placebo-controlled Phase IIa clinical trial for ASD initiated in July 2023 [S1].
• The company outlicensed its SCI-160 program to Polyrizon in August 2024 and is no longer developing this product [S1].
• SciSparc Nutraceuticals, a subsidiary, owns the Wellution™ brand and generated revenues of $856 thousand in 2025, with cost of goods sold of $225 thousand [S1].
• The company has a history of reverse share splits, including a 1-for-9 split announced in March 2026 and a 1-for-20 split effective July 2025 [N3][N2].
• SciSparc has entered agreements to acquire patent portfolios for endoscopic technologies, indicating expansion into multi-billion dollar markets [N4].
• The company holds controlling interests in subsidiaries such as Nexentis and has engaged in mergers and loan agreements with entities like AutoMax Motors [S1][N6].
• Financial snapshot as of June 30, 2025: cash and equivalents $1.545 million, current assets $2.749 million, current liabilities $5.038 million, current ratio 0.55, cash ratio 0.31, revenue $461 thousand for Q2 2025, EPS basic and diluted $17.92 per share for Q2 2025 [sec_financial_snapshot].
• The company has incurred significant losses historically, with a net loss of $3.535 million reported for fiscal year 2020 and an accumulated deficit of approximately $87 million as of December 31, 2025 [S1].
• SciSparc's pharmaceutical operations depend on raising additional funds; cash and equivalents are insufficient to fund planned operations for at least one year beyond the latest filing date [S1].
• The company faces competition from other cannabinoid-based pharmaceutical developers and established drugs with FDA approval for related indications [S1].
• Recent news includes a patent application for depression therapy in collaboration with Clearmind Medicine, acquisition moves by NeuroThera, and patent portfolio acquisitions [N1][N2][N4].